PDCD1 and melanoma: Monoclonal antibodies targeting PD-1, Lambrolizumab, Nivolumab and Pembrolizumab [28] have favorable immunotherapeutic effects in treatment of a variety of cancers including melanoma, renal and lung cancers [29, 30].